Related Experiment Video
Updated: May 30, 2026
06:55
Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
Published on: February 22, 2020
A novel prognostic model for extranodal natural killer/T-cell lymphoma
Jia-Jia Huang1, Ying-Jie Zhu, Yi Xia
1State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-Sen University, 651 Dong Feng RD East, Guangzhou, Guangdong, People's Republic of China.
Medical Oncology (Northwood, London, England)
|July 26, 2011
Summary
A new prognostic model for extranodal Natural Killer (NK)/T-cell lymphoma was developed using absolute lymphocyte count, B symptoms, and advanced stage. This model effectively stratifies patients into distinct risk groups for improved survival prediction and treatment guidance.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Extranodal Natural Killer (NK)/T-cell lymphoma is a rare and aggressive neoplasm.
- Existing prognostic models lack sufficient discriminatory power for certain patient subgroups.
Purpose of the Study:
- To develop and validate a novel prognostic model for extranodal NK/T-cell lymphoma.
- To improve risk stratification and guide treatment decisions for affected patients.
Main Methods:
- Retrospective analysis of 146 patients with newly diagnosed extranodal NK/T-cell lymphoma.
- Cox regression analysis to identify independent predictors of survival.
- Development of a novel prognostic model based on identified predictors.
Main Results:
- The novel model identified absolute lymphocyte count, B symptoms, and advanced stage as independent predictors of poorer survival.
- Patients were categorized into three risk groups with significantly different 5-year overall survival rates (71.6% for low-risk, 55.5% for intermediate-risk, and 0% for high-risk).
- The new model demonstrated better predictive discrimination compared to existing indices within specific patient subgroups.
Conclusions:
- The novel prognostic model offers improved risk stratification for extranodal NK/T-cell lymphoma.
- This model can aid clinicians in treatment selection and patient management.
- Further validation in prospective studies is warranted.
